Eledon Pharmaceuticals, Inc.
ELDN
$2.06
-$2.04-49.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -72.69% | 85.44% | -157.97% | 271.40% | -90.03% |
| Total Depreciation and Amortization | -- | -- | 11.39% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.42% | -128.87% | 128.30% | -381.46% | 132.29% |
| Change in Net Operating Assets | 297.20% | -15.56% | -122.30% | 115.25% | 1,092.45% |
| Cash from Operations | -10.29% | 15.42% | -61.33% | -51.39% | 11.06% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 284.33% | 108.21% | -270.11% | 35.71% | -303.55% |
| Cash from Investing | 284.33% | 108.21% | -270.11% | 35.71% | -303.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -99.86% | 1,417.45% | -89.01% | 4,807,000.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -99.86% | 1,417.45% | -89.01% | 4,807,000.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 77.14% | -187.35% | 171.54% | -194.62% | 1,854.36% |